Expanding Immunotheapy Benefit in Metastatic RCC

Discussion of a phase I trial of the checkpoint inhibitor atezolizumab in metastatic renal carcinoma.

Episode metadata supplied by the publisher feed · Published Jan 11, 2016

Embed this episode

Attribution link and audio player

NOW PLAYING

Expanding Immunotheapy Benefit in Metastatic RCC

0:00 6:33

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Similar Episodes

No similar episodes found.

No similar podcasts found.

This episode is 6 minutes long.

This episode was published on January 11, 2016.

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!